Cite

HARVARD Citation

    Meyer, S. et al. (2016). Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting. MAbs. 8 (1), pp. 87-98. [Online]. 
  
Back to record